Ultromics

Executive Summary

Ultromics is a UK-based medical AI company specializing in the analysis of routine echocardiograms using its FDA-cleared EchoGo® platform. The platform employs machine learning to detect complex cardiac conditions such as heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis from standard echo video clips. By automating the interpretation of echocardiograms, Ultromics aims to improve diagnostic accuracy, reduce variability, and integrate seamlessly into existing clinical workflows. Founded in 2017 and headquartered in Oxford, the company addresses a significant unmet need in non-invasive cardiac diagnostics, where misdiagnosis of conditions like HFpEF is common. With its clinically validated AI, Ultromics has the potential to enhance early detection and patient outcomes while reducing healthcare costs. The company is privately held and has not disclosed its funding stage or valuation, but its technology represents a promising advance in the application of AI to cardiovascular medicine.

Upcoming Catalysts (preview)

• Q3 2026Additional FDA Clearance for New Indication (e.g., Valvular Heart Disease)70% success
• Q3 2026Strategic Partnership with Major Hospital Network or Device Manufacturer60% success
• Q4 2026Series B or Significant Financing Round50% success